000916863 001__ 916863
000916863 005__ 20230224084254.0
000916863 0247_ $$2doi$$a10.2967/jnumed.121.263194
000916863 0247_ $$2ISSN$$a0097-9058
000916863 0247_ $$2ISSN$$a0022-3123
000916863 0247_ $$2ISSN$$a0161-5505
000916863 0247_ $$2ISSN$$a1535-5667
000916863 0247_ $$2ISSN$$a2159-662X
000916863 0247_ $$2Handle$$a2128/33579
000916863 0247_ $$2pmid$$a35649653
000916863 0247_ $$2WOS$$aWOS:000807305900002
000916863 037__ $$aFZJ-2023-00155
000916863 082__ $$a610
000916863 1001_ $$0P:(DE-HGF)0$$aMinoshima, Satoshi$$b0
000916863 245__ $$a18 F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies
000916863 260__ $$aNew York, NY$$bSoc.$$c2022
000916863 3367_ $$2DRIVER$$aarticle
000916863 3367_ $$2DataCite$$aOutput Types/Journal article
000916863 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673611260_32709
000916863 3367_ $$2BibTeX$$aARTICLE
000916863 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916863 3367_ $$00$$2EndNote$$aJournal Article
000916863 520__ $$aSince the invention of 18F-FDG as a neurochemical tracer in the 1970s, 18F-FDG PET has been used extensively for dementia research and clinical applications. FDG, a glucose analog, is transported into the brain via glucose transporters and metabolized in a concerted process involving astrocytes and neurons. Although the exact cellular mechanisms of glucose consumption are still under investigation, 18F-FDG PET can sensitively detect altered neuronal activity due to neurodegeneration. Various neurodegenerative disorders affect different areas of the brain, which can be depicted as altered 18F-FDG uptake by PET. The spatial patterns and severity of such changes can be reproducibly visualized by statistical mapping technology, which has become widely available in the clinic. The differentiation of 3 major neurodegenerative disorders by 18F-FDG PET, Alzheimer disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), has become standard practice. As the nosology of FTD evolves, frontotemporal lobar degeneration, the umbrella term for pathology affecting the frontal and temporal lobes, has been subclassified clinically into behavioral variant FTD; primary progressive aphasia with 3 subtypes, semantic, nonfluent, and logopenic variants; and movement disorders including progressive supranuclear palsy and corticobasal degeneration. Each of these subtypes is associated with differential 18F-FDG PET findings. The discovery of new pathologic markers and clinicopathologic correlations via larger autopsy series have led to newly recognized or redefined disease categories, such as limbic-predominant age-related TDP-43 encephalopathy, hippocampus sclerosis, primary age-related tauopathy, and argyrophilic grain disease, which have become a focus of investigations by molecular imaging. These findings need to be integrated into the modern interpretation of 18F-FDG PET. Recent pathologic investigations also have revealed a high prevalence, particularly in the elderly, of mixed dementia with overlapping and coexisting pathologies. The interpretation of 18F-FDG PET is evolving from a traditional dichotomous diagnosis of AD versus FTD (or DLB) to a determination of the most predominant underlying pathology that would best explain the patient's symptoms, for the purpose of care guidance. 18F-FDG PET is a relatively low cost and widely available imaging modality that can help assess various neurodegenerative disorders in a single test and remains the workhorse in clinical dementia evaluation.
000916863 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000916863 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916863 7001_ $$0P:(DE-HGF)0$$aCross, Donna$$b1
000916863 7001_ $$0P:(DE-HGF)0$$aThientunyakit, Tanyaluck$$b2
000916863 7001_ $$0P:(DE-HGF)0$$aFoster, Norman L.$$b3
000916863 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b4$$ufzj
000916863 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.121.263194$$gVol. 63, no. Supplement 1, p. 2S - 12S$$nSupplement 1$$p2S - 12S$$tJournal of nuclear medicine$$v63$$x0097-9058$$y2022
000916863 8564_ $$uhttps://juser.fz-juelich.de/record/916863/files/2S.full.pdf$$yOpenAccess
000916863 909CO $$ooai:juser.fz-juelich.de:916863$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000916863 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b4$$kFZJ
000916863 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000916863 9141_ $$y2022
000916863 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2021$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NUCL MED : 2021$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916863 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000916863 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000916863 920__ $$lyes
000916863 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000916863 980__ $$ajournal
000916863 980__ $$aVDB
000916863 980__ $$aUNRESTRICTED
000916863 980__ $$aI:(DE-Juel1)INM-2-20090406
000916863 9801_ $$aFullTexts